Cargando…

A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy

(1) Background: Left ventricular hypertrophy, myocardial disarray and interstitial fibrosis are the hallmarks of hypertrophic cardiomyopathy (HCM). Access to the myocardium for diagnostic purposes is limited. Circulating biomolecules reflecting the myocardial disease processes could improve the earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Thottakara, Tilo, Lund, Natalie, Krämer, Elisabeth, Kirchhof, Paulus, Carrier, Lucie, Patten, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615621/
https://www.ncbi.nlm.nih.gov/pubmed/34827715
http://dx.doi.org/10.3390/biom11111718
_version_ 1784604148535132160
author Thottakara, Tilo
Lund, Natalie
Krämer, Elisabeth
Kirchhof, Paulus
Carrier, Lucie
Patten, Monica
author_facet Thottakara, Tilo
Lund, Natalie
Krämer, Elisabeth
Kirchhof, Paulus
Carrier, Lucie
Patten, Monica
author_sort Thottakara, Tilo
collection PubMed
description (1) Background: Left ventricular hypertrophy, myocardial disarray and interstitial fibrosis are the hallmarks of hypertrophic cardiomyopathy (HCM). Access to the myocardium for diagnostic purposes is limited. Circulating biomolecules reflecting the myocardial disease processes could improve the early detection of HCM. Circulating miRNAs have been found to reflect disease processes in several cardiovascular diseases. (2) Methods: We quantified circulating miRNA molecules in the plasma of 24 HCM and 11 healthy controls using the Human v3 miRNA Expression Assay Kit Code set (Nanostring Tech., Seattle, WA, USA) and validated differentially expressed miRNAs using RT-PCR. (3) Results: In comparison to healthy controls, the levels of six miRNAs (miR-1, miR-3144, miR-4454, miR-495-3p, miR-499a-5p and miR-627-3p) were higher in the plasma of HCM patients than healthy individuals (p < 0.05). Of these, higher levels of miR-1, miR-495 and miR-4454 could be validated by real-time PCR. In addition, elevated miR-4454 levels were significantly correlated with cardiac fibrosis, detected by magnetic resonance imaging in HCM patients. (4) Conclusions: Circulating miR-1, miR-495-3p and miR-4454 levels are elevated in the plasma of HCM patients. To the best of our knowledge, this is the first report showing a correlation between miR-4454 levels and cardiac fibrosis in HCM. This suggests miR-4454 as a potential biomarker for fibrosis in these patients.
format Online
Article
Text
id pubmed-8615621
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86156212021-11-26 A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy Thottakara, Tilo Lund, Natalie Krämer, Elisabeth Kirchhof, Paulus Carrier, Lucie Patten, Monica Biomolecules Article (1) Background: Left ventricular hypertrophy, myocardial disarray and interstitial fibrosis are the hallmarks of hypertrophic cardiomyopathy (HCM). Access to the myocardium for diagnostic purposes is limited. Circulating biomolecules reflecting the myocardial disease processes could improve the early detection of HCM. Circulating miRNAs have been found to reflect disease processes in several cardiovascular diseases. (2) Methods: We quantified circulating miRNA molecules in the plasma of 24 HCM and 11 healthy controls using the Human v3 miRNA Expression Assay Kit Code set (Nanostring Tech., Seattle, WA, USA) and validated differentially expressed miRNAs using RT-PCR. (3) Results: In comparison to healthy controls, the levels of six miRNAs (miR-1, miR-3144, miR-4454, miR-495-3p, miR-499a-5p and miR-627-3p) were higher in the plasma of HCM patients than healthy individuals (p < 0.05). Of these, higher levels of miR-1, miR-495 and miR-4454 could be validated by real-time PCR. In addition, elevated miR-4454 levels were significantly correlated with cardiac fibrosis, detected by magnetic resonance imaging in HCM patients. (4) Conclusions: Circulating miR-1, miR-495-3p and miR-4454 levels are elevated in the plasma of HCM patients. To the best of our knowledge, this is the first report showing a correlation between miR-4454 levels and cardiac fibrosis in HCM. This suggests miR-4454 as a potential biomarker for fibrosis in these patients. MDPI 2021-11-18 /pmc/articles/PMC8615621/ /pubmed/34827715 http://dx.doi.org/10.3390/biom11111718 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thottakara, Tilo
Lund, Natalie
Krämer, Elisabeth
Kirchhof, Paulus
Carrier, Lucie
Patten, Monica
A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title_full A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title_fullStr A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title_full_unstemmed A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title_short A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy
title_sort novel mirna screen identifies mirna-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615621/
https://www.ncbi.nlm.nih.gov/pubmed/34827715
http://dx.doi.org/10.3390/biom11111718
work_keys_str_mv AT thottakaratilo anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT lundnatalie anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT kramerelisabeth anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT kirchhofpaulus anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT carrierlucie anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT pattenmonica anovelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT thottakaratilo novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT lundnatalie novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT kramerelisabeth novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT kirchhofpaulus novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT carrierlucie novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy
AT pattenmonica novelmirnascreenidentifiesmirna4454asacandidatebiomarkerforventricularfibrosisinpatientswithhypertrophiccardiomyopathy